X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-02-21 | GLYC | Invus Public Equities, L.P. | 10% | P - Purchase | $1.78 | +400,000 | 8,489,064 | +5% | +$712,255 | |||||
| M | 2023-02-15 | GLYC | Invus Public Equities, L.P. | 10% | P - Purchase | $2.00 | +1,515,266 | 8,089,064 | +23% | +$3,027,929 | |||||
2023-02-09 | GLYC | Invus Public Equities, L.P. | 10% | P - Purchase | $3.24 | +11,451 | 6,573,798 | 0% | +$37,123 | ||||||
| M | 2023-01-25 | GLYC | Sandell Scott D | 10% | S - Sale | $3.14 | -3,652,016 | 4,967,530 | -42% | -$11,484,515 | |||||
2023-01-05 | GLYC | Sandell Scott D | 10% | S - Sale | $2.76 | -71,362 | 8,619,546 | -1% | -$196,859 | ||||||
| M | 2022-12-30 | GLYC | Sandell Scott D | 10% | S - Sale | $2.98 | -398,133 | 8,690,908 | -4% | -$1,185,886 | |||||
2022-12-22 | GLYC | Rock Edwin | Chief Medical Officer | P - Purchase | $2.25 | +110,000 | 310,000 | +55% | +$247,500 | ||||||
2022-11-17 | GLYC | Junius Daniel M | Dir | P - Purchase | $1.87 | +20,000 | 63,250 | +46% | +$37,400 | ||||||
| M | 2022-11-14 | GLYC | Rock Edwin | Chief Medical Officer | P - Purchase | $1.55 | +200,000 | 200,000 | New | +$309,000 | |||||
2022-11-11 | GLYC | Pearson Timothy R | Dir | P - Purchase | $1.29 | +19,400 | 24,650 | +370% | +$25,026 | ||||||
2022-11-11 | GLYC | Semerjian Harout | CEO | P - Purchase | $1.29 | +25,000 | 25,000 | New | +$32,250 | ||||||
2022-11-11 | GLYC | Hahn Brian M. | SVP Finance, CFO | P - Purchase | $1.06 | +20,000 | 56,843 | +54% | +$21,200 | ||||||
2022-11-11 | GLYC | Magnani John L. | SVP of Research, CSO | P - Purchase | $1.17 | +45,045 | 370,923 | +14% | +$52,703 | ||||||
2022-11-11 | GLYC | Girard Armand | SVP, Chief Business Officer | P - Purchase | $1.05 | +6,500 | 29,161 | +29% | +$6,825 | ||||||
2022-03-09 | GLYC | Magnani John L. | SVP of Research, CSO | S - Sale | $1.09 | -3,227 | 325,878 | -1% | -$3,517 | ||||||
2022-03-09 | GLYC | Girard Armand | SVP, Chief Business Officer | S - Sale | $1.09 | -2,339 | 22,661 | -9% | -$2,550 | ||||||
2022-03-09 | GLYC | Hahn Brian M. | SVP Finance, CFO | S - Sale | $1.09 | -2,917 | 36,843 | -7% | -$3,180 | ||||||
2021-11-16 | GLYC | Andrews Patricia S | Dir | P - Purchase | $2.05 | +40,000 | 45,250 | +762% | +$82,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |